Who Are the Core Customers of DexCom Company?

DexCom users originally centered on the Type 1 diabetes (T1D) population who require real-time CGM for survival and insulin dosing; endocrinologists and pediatricians remain primary prescribers. In 2025, T1D still drives clinical trust and high-revenue device bundles.

By 2025 the fastest-growing segment is non-insulin-dependent Type 2 diabetes (T2D) patients after the 2024 launch and 2025 expansion of Stelo, targeting an estimated 25,000,000 Americans with T2D not on insulin; insurers and primary care doctors increasingly recommend CGM for medication adjustment and risk reduction.

DexCom serves a mixed base: direct consumers (patients and athletes), healthcare providers (endocrinologists, primary care doctors), and payers (insurers, Medicare). Revenue mix in 2025 reflects both prescription sales to clinics/hospitals and retail adoption through pharmacies and direct channels.

The T2D non-insulin segment emerged as the single most important growth driver in 2025, expanding addressable market and boosting sensor volumes; DexCom reported accelerating unit growth in consumer-oriented lines while maintaining high ARPU from T1D prescription customers. See the Brand Story of DexCom Company for context: Brand Story of DexCom Company

The primary DexCom customers are concentrated in the US where favorable reimbursement and wide insurer coverage drive adoption among people with diabetes, especially type 1 and insulin-using type 2 patients; Medicare coverage expansion in 2025 to all insulin users and certain non-insulin hypoglycemia cases meaningfully increased addressable market and device uptake.

Outside the US, DexCom users are growing fastest in Western Europe and Japan where broader public funding and pharmacy channel access expanded in 2025; insurers and payers in these markets increasingly support outpatient retail access for CGM devices.

DexCom, Inc. shows greatest strength in US revenue mix and clinical adoption: sensors and transmitters dominate ambulatory glucose monitoring in endocrinology and primary care settings, with hospitals and clinics using systems for inpatient and perioperative glycemic management; pharmacy channel penetration reduced prescriber admin burden and broadened reach.

Fastest growth in 2025/2026 appears in OUS retail pharmacy channels, pediatric and gestational diabetes segments, and among non-insulin type 2 patients where payer policy changes and cost-to-patient reductions improve access; see Product Model of DexCom Company for device and channel specifics.

DexCom customers now include both prescription-dependent DexCom users (T1D, insulin-intensive T2D) and OTC wellness buyers through Stelo; this dual product strategy targets a total addressable market roughly 10x the original T1D niche and opens channels to athletes, pregnant women, and metabolic-health consumers.

Keeping G7 as a prescription-only medical device preserves endorsement from endocrinologists and primary care doctors recommending DexCom and sustains insurer and Medicare coverage dynamics; clinical data and FDA labeling maintain trust among healthcare providers prescribing DexCom.

Software integration and data ecosystems lock DexCom target market users into continuous glucose monitoring workflows, driving renewals and repeat demand across sensors and transmitters; DexCom retains high gross margin economics-above 60% as of 2026-while increasing lifetime value.

The strongest growth lever is platform-driven scale: interoperable software, data services, and consumer OTC distribution (Stelo) reduce insurance friction and accelerate adoption among non-insulin T2D and wellness buyers, while prescription G7 preserves clinician channels and payer relationships.